Long-Term Follow-Up Results of Topical Imiquimod Treatment in Basal Cell Carcinoma


Creative Commons License

BOSTANCI S., KOÇYİĞİT P., Vural S., HEPER A., Botsali A.

DERMATOLOGIC SURGERY, cilt.44, sa.1, ss.36-41, 2018 (SCI-Expanded, Scopus) identifier identifier identifier

Özet

BACKGROUND Imiquimod 5% topical cream is approved for treatment of superficial basal cell carcinoma (BCC). Data on the long-term efficacy and usage in other BCC subtypes are scarce.